MedTrace Logo

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

NCT04347005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-11-16

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Cohort 1: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 2: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 3: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 4: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 5: AR882

Single dose of AR882 or matching placebo

DRUG

Cohort 6: AR882 Food Effect

Single dose of AR882 or matching placebo in a fed state

DRUG

Cohort 7: AR882 Solid Oral Formulation

Single dose of AR882 or matching placebo

DRUG

Cohort 8: AR882 in combination with allopurinol

Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol

DRUG

Cohort 9: AR882 in combination with febuxostat

Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat

Sponsors & Collaborators

  • Arthrosi Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2019-07-31
Completion
2019-07-31
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04347005 on ClinicalTrials.gov